ALBO

Albireo Pharma, Inc. [ALBO] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

ALBO Stock Summary

In the News

11:18 28 Mar 2024 ALBO

Is Albireo Pharma (ALBO) Stock Outpacing Its Medical Peers This Year?

Here is how Albireo Pharma (ALBO) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.

02:19 28 Mar 2024 ALBO

Albireo Pharma: Elucidating The Ipsen Buyout (Rating Upgrade)

Albireo Pharma, Inc. has entered into an agreement to get acquired by Ipsen. Bylvay is already approved for PFIC. Nevertheless, the stellar drug is poised to gain additional labels for Alagille syndrome and biliary atresia.

11:00 28 Mar 2024 ALBO

2 Tiny Nasdaq Stocks Making Major Merger Moves Monday

The market is moving higher, and these small companies are helping.

08:35 28 Mar 2024 ALBO

Albireo Pharma, Inc. (ALBO) Q3 2022 Earnings Call Transcript

Albireo Pharma, Inc. (NASDAQ:ALBO ) Q3 2022 Results Conference Call November 8, 2022 4:30 PM ET Company Participants Hans Vitzthum - Managing Director, LifeSci Advisors Ron Cooper - President and Chief Executive Officer Jan Musin - Chief Scientific Officer, Head of R&D Pamela Stephenson - Chief Commercial Officer Simon Harford - Chief Financial Officer Conference Call Participants Miriam Nolan - Jefferies Brian Skorney - Baird Ritu Baral - Cowen Seamus Fernandez - Guggenheim Tim Lugo - William Blair Andreas Argyrides - Wedbush Securities Thomas Yip - H. C. Wainwright Operator Good afternoon.

06:48 28 Mar 2024 ALBO

Albireo Pharma (ALBO) Reports Q3 Loss, Tops Revenue Estimates

Albireo Pharma (ALBO) delivered earnings and revenue surprises of -1.61% and 1.58%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

08:30 28 Mar 2024 ALBO

Albireo to Present Late Breaking Bylvay® (odevixibat) Data at AASLD 2022

– Oral late breaker with new results from positive Phase 3 ASSERT study in Alagille syndrome (ALGS)

08:30 28 Mar 2024 ALBO

Albireo to Report Q3 2022 Financial Results on November 8, 2022

Conference call and webcast to be held at 4:30 pm ET Conference call and webcast to be held at 4:30 pm ET

06:44 28 Mar 2024 ALBO

Albireo: Strong Phase 3 Data Foretells More Upside

Sales for Bylvay's first approved indication is increasing. The company recently posted superb data for an orphan disease known as Alagille Syndrome.

01:32 28 Mar 2024 ALBO

Albireo (ALBO) Up on Results From Alagille Syndrome Study

Albireo Pharma (ALBO) reports positive top-line data from a late-stage study evaluating Bylvay in Alagille syndrome. The study meets the primary and key secondary endpoint Stock up.

09:29 28 Mar 2024 ALBO

Albireo's stock is up 10% on plans to seek FDA approval for drug for rare disorder

Shares of Albireo Pharma Inc. ALBO, +6.86% gained 10.4% in premarket trading on Tuesday after the company said it is seeking Food and Drug Administration approval to use its medication Bylvay as a treatment for Alagille syndrome, a rare inherited disorder that can result in liver damage. Albireo said a Phase 3 clinical trial evaluating the drug met its primary endpoint and a key secondary endpoint.

ALBO Financial details

Company Rating
Neutral
Market Cap
915.89M
Income
-137.38M
Revenue
57.39M
Book val./share
5.09
Cash/share
11.32
Dividend
-
Dividend %
-
Employees
130
Optionable
No
Shortable
Yes
Earnings
15 May 2023
P/E
-6.86
Forward P/E
-
PEG
12.47
P/S
36.83
P/B
8.67
P/C
3.9
P/FCF
-8.94
Quick Ratio
5.94
Current Ratio
6.32
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-7.04
EPS next Y
-
EPS next Q
-
EPS this Y
5.64%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
20.33%
Revenue last 5Y
734.95%
Revenue Q/Q
19.81%
EPS Q/Q
-10.55%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
0.23%
Inst Trans
0%
ROA
-39%
ROE
-105%
ROC
-0.39%
Gross Margin
93%
Oper. Margin
-448%
Profit Margin
-508%
Payout
-
Shs Outstand
20.74M
Shs Float
14.22M
-
-
-
-
Target Price
44
52W Range
16.02-45.23
52W High
-1.89%
52W Low
+175.94%
RSI
-
Rel Volume
2.18
Avg Volume
566.9K
Volume
1.24M
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-0.23%
-
-
-
-
Beta
1.03556
-
-
Volatility
0.04%, 0.04%
Prev Close
0%
Price
44.15
Change
-1.67%

ALBO Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric History 2017-12-312018-12-312019-12-312020-12-31 2021-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
01.090.770.522.11
Net income per share
-3.12-3.94-5.77-7.45-7.87
Operating cash flow per share
-3.53-2.29-4.25-6.32-5.6
Free cash flow per share
-3.55-2.3-4.3-6.33-5.62
Cash per share
6.811410.615.7212.91
Book value per share
8.3510.487.4911.349.14
Tangible book value per share
6.1496.110.268.24
Share holders equity per share
8.3510.487.4911.349.14
Interest debt per share
0.01-0.410.431.311.25
Market cap
200.17M287.07M316.17M599.52M447.65M
Enterprise value
146.94M123.18M184.32M357.87M209.55M
P/E ratio
-8.2-6.23-4.41-5.04-2.96
Price to sales ratio
200.17K22.5332.8172.1611.03
POCF ratio
-7.26-10.71-5.97-5.93-4.16
PFCF ratio
-7.21-10.69-5.91-5.93-4.14
P/B Ratio
3.072.343.393.312.55
PTB ratio
3.072.343.393.312.55
EV to sales
146.94K9.6719.1343.085.16
Enterprise value over EBITDA
-5.99-3.25-3.22-3.72-10.57
EV to operating cash flow
-5.33-4.6-3.48-3.54-1.95
EV to free cash flow
-5.29-4.59-3.45-3.54-1.94
Earnings yield
-0.12-0.16-0.23-0.2-0.34
Free cash flow yield
-0.14-0.09-0.17-0.17-0.24
Debt to equity
0000.050.06
Debt to assets
0000.030.03
Net debt to EBITDA
2.174.332.32.5212.01
Current ratio
6.9413.077.4910.365.93
Interest coverage
-614.437.83-11.54-8.47-8.86
Income quality
1.130.580.840.943.16
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
15.25K1.422.385.110
Research and developement to revenue
12.99K2.494.739.242.03
Intangibles to total assets
0.240.090.10.060.06
Capex to operating cash flow
0.0100.0100
Capex to revenue
-1900-0.06-0.01-0.01
Capex to depreciation
-5.43-1.36-4.25-0.41-1.7
Stock based compensation to revenue
3.7K0.440.791.760.39
Graham number
24.2130.4831.1743.5840.23
ROIC
-0.38-0.31-0.75-0.56-2.96
Return on tangible assets
-0.44-0.27-0.49-0.44-0.53
Graham Net
5.868.824.829.196.46
Working capital
47.08M154.83M122.88M236.58M223.58M
Tangible asset value
47.99M105.38M75.9M163.97M158.35M
Net current asset value
47.04M104.82M69.89M157.49M142.49M
Invested capital
0000.050.06
Average receivables
548K1.82M1.46M01.64M
Average payables
1.16M2.85M4.57M5.03M5.9M
Average inventory
000097K
Days sales outstanding
264.99K83.510029.43
Days payables outstanding
00790.2801.75K
Days of inventory on hand
000052.22
Receivables turnover
04.370012.4
Payables turnover
000.4600.21
Inventory turnover
00006.99
ROE
-0.37-0.38-0.77-0.66-0.86
Capex per share
-0.02-0.01-0.040-0.02

Quarterly Fundamentals Overview

Last date of statement is 2022-09-30 for Q3

Metric History 2021-09-302021-12-312022-03-312022-06-30 2022-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.191.690.350.420.5
Net income per share
2.96-0.57-2.34-2.18-1.95
Operating cash flow per share
-1.43-0.72-1.83-1.86-1.51
Free cash flow per share
-1.44-0.73-1.84-1.89-1.51
Cash per share
13.6412.8611.189.2411.32
Book value per share
9.449.17.655.85.09
Tangible book value per share
8.548.216.764.924.21
Share holders equity per share
9.449.17.655.85.09
Interest debt per share
0.690.690.670.660.13
Market cap
600.88M449.26M578.09M388.96M380.53M
Enterprise value
348.19M211.16M371.52M218.15M158.05M
P/E ratio
2.63-10.25-3.19-2.28-2.48
Price to sales ratio
16413.8184.6247.438.7
POCF ratio
-21.86-32.34-16.33-10.69-12.84
PFCF ratio
-21.72-31.71-16.22-10.49-12.83
P/B Ratio
3.312.563.93.423.8
PTB ratio
3.312.563.93.423.8
EV to sales
95.036.4954.3826.5816.08
Enterprise value over EBITDA
5.42-18.54-9.42-5.88-4.58
EV to operating cash flow
-12.67-15.2-10.49-5.99-5.33
EV to free cash flow
-12.58-14.9-10.42-5.88-5.33
Earnings yield
0.1-0.02-0.08-0.11-0.1
Free cash flow yield
-0.05-0.03-0.06-0.1-0.08
Debt to equity
0.050.060.070.090
Debt to assets
0.030.030.040.040
Net debt to EBITDA
-3.9320.915.244.66.44
Current ratio
8.25.937.264.496.32
Interest coverage
19.28-3.53-13.75-13.55-13.7
Income quality
-0.481.270.830.910.78
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00.99000
Research and developement to revenue
5.750.633.212.792.37
Intangibles to total assets
0.060.060.070.080.05
Capex to operating cash flow
0.010.020.010.020
Capex to revenue
-0.05-0.01-0.03-0.080
Capex to depreciation
-2.02-2.61-2.06-8.15-0.32
Stock based compensation to revenue
1.830.080.510.440.36
Graham number
25.0910.7920.0616.8714.96
ROIC
0.31-0.05-0.27-0.32-0.35
Return on tangible assets
0.2-0.04-0.19-0.2-0.13
Graham Net
7.736.445.443.480.22
Working capital
238.75M223.58M197.22M152.16M201.02M
Tangible asset value
164.46M158.35M130.93M96.42M82.81M
Net current asset value
157.17M142.49M115.65M80.42M17.69M
Invested capital
0.050.060.070.090
Average receivables
653.5K2.29M2.27M1.56M1.94M
Average payables
6.46M6.87M6.44M5.88M6.17M
Average inventory
98K195K1.01M1.96M2.62M
Days sales outstanding
32.19.0616.820.2818.57
Days payables outstanding
1.51K633.992.45K625.591.02K
Days of inventory on hand
40.9318.88700.38243.09463.09
Receivables turnover
2.89.945.364.444.85
Payables turnover
0.060.140.040.140.09
Inventory turnover
2.24.770.130.370.19
ROE
0.31-0.06-0.31-0.38-0.38
Capex per share
-0.01-0.01-0.01-0.030

ALBO Frequently Asked Questions

What is Albireo Pharma, Inc. stock symbol ?

Albireo Pharma, Inc. is a US stock , located in Boston of Ma and trading under the symbol ALBO

Is Albireo Pharma, Inc. buy or a sell ?

3 stock analysts have 3 predictions with a medium analyst target price of $44. The lowest prediction is $42 and the highest is $48

What is ALBO stock prediction ?

What is Albireo Pharma, Inc. stock quote today ?

Albireo Pharma, Inc. stock price is $44.15 today.

Is Albireo Pharma, Inc. stock public?

Yes, Albireo Pharma, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Same Sector
Check Those